(Q33745179)

29 July 2017

1 reference

title

Recombinant antibody constructs in cancer therapy (English)

1 reference

29 July 2017

1 reference

Hudson PJ

1

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Current Opinion in Immunology

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

548-557

1 reference

The development of monoclonal antibodies for the therapy of cancer.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Recombinant antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

1 reference

7 January 2021

Use of rituximab, the new FDA-approved antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Antibody phage display technology and its applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Display technologies expand their horizons

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Model and Simulation of Multivalent Binding to Fixed Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

An efficient route to human bispecific IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

A dimeric bispecific miniantibody combines two specificities with avidity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Dual specificity antibodies using a double-stranded oligonucleotide bridge

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Multiple event activation of a generic prodrug trigger by antibody catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Targeted gene delivery to mammalian cells by filamentous bacteriophage

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Dendritic cell vaccines for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Antigen mimicry by an anti-idiotypic antibody single chain variable fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Effects of substitutions in the binding surface of an antibody on antigen affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Electrostatic complementarity at protein/protein interfaces

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Different Equilibrium Stability Behavior of ScFv Fragments: Identification, Classification, and Improvement by Protein Engineering†

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen 1 1Edited by P. E. Wright

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Removal of the conserved disulfide bridges from the scfv fragment of an antibody: effects on folding kinetics and aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Antibody affinity maturation using bacterial surface display.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Reproducing the natural evolution of protein structural features with the selectively infective phage (SIP) technology. The kink in the first strand of antibody kappa domains.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

Human monoclonal antibodies: the emperor's new clothes?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900013-8

7 January 2021

10.1016/S0952-7915(99)00013-8

Identifiers

DOI

1 reference

29 July 2017

1 reference